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1. Introduction 
Due to transparent ocular media, it is relatively easy to observe intraocular tissues such as 
the vitreous and retina without invasion, and various administration approaches including 
intravitreal and subretinal injection, or implantation can be applicable. Since the eye-ball is a 
closed organ, novel therapeutic molecules such as an antisense oligonucleotide for 
cytomegalovirus retinitis (Fomivirsen; Vitraven®, Isis Pharmaceuticals, Inc., Carlsbad, CA 
U.S. and Novartis, Basel, Switzerland), an aptamer (e.g. Pegaptanib sodium; Macugen®, 
Pfizer, Inc., New York, NY, U.S.) or a small interfering RNA for neovascular (wet) age-
related macular degeneration (AMD), have been investigated in human eyes before their 
applications for systemic diseases. In addition, many injectable or implantable drug delivery 
systems for chronic vitreoretinal diseases including AMD, diabetic macular edema, retinal 
vein occlusion, uveitis, and retinitis pigmentosa (RP), using polymer technology and/or 
mechanical engineering, have been developing (Figure 1).  
This chapter focuses on drug delivery systems under clinical applications and in late 
experimental stage for the treatment of both wet and atrophic (dry) AMD (Table 1). 
2. Significance of drug delivery systems for AMD 
For the treatment of wet AMD, a standard therapy is monthly intravitreal injections of 
ranibizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody 
fragment (Lucentis®, Genentech, Inc., South San Francisco, CA, U.S.) (Genentech Inc.) and 
photodynamic therapy (PDT) by systemic administration of verteporfin (Visudyne®, QLT 
Ophthalmics, Inc., Menlo Park, CA, U.S.). The monthly cost of Lucentis® is about $2,000 and 
that means effective treatment by Lucentis® faces a serious social problem (Martin et al., 
2010, Gower et al., 2010, Patel et al., 2010). Also frequent intravitreal injections might cause 
several complications, it has been reported that prevalence of lens damage, endophthalmitis 
and rhegmatogenous retinal detachment were 0.006% (2 of 32,318 injections) (Meyer, 
Rodrigues et al., 2010), 0.029% (3 of 10,254 cases) (Pilli et al., 2008) and 0.013% (5 of 35,942 
injections) (Meyer, Michels et al., 2010), respectively. In addition, recently sustained 
elevation of intraocular pressure (IOP) after intravitreal injections of anti-VEGF agents has 
been reported (Good et al., 2011). Although the mechanism of IOP elevation is unclear, 
aggregation of proteins and/or leaching of silicone from the syringe barrel and rubber 
stopper might cause to clog the trabecular meshwork. It has also been demonstrated that 
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aggregated proteins induce a more significant immunological response than non-aggregated 
proteins (Rosenberg, 2006). Furthermore, a lack of selective targeting of verteporfin to 
neovascular endothelial cells causes to damage the normal retinal tissues such as the retinal 
pigment epithelium (RPE) and photoreceptors. Therefore, it is necessary to develop drug 
delivery systems which can be easily and non-invasively administered, have long-term 
controlled-release by a single administration, and/or selective-targeting potency to the 
pathologic tissues for the treatment of AMD to overcome the disadvantages in the current 
wet AMD therapy.  
 
Fig. 1. Example of drug delivery systems for the treatment of AMD 
On the other hand, tachyphylaxis is a diminished therapeutic response to a drug after 
repeated administrations over time. It has been reported that 8.5% (5 of 59 patients) of wet 
AMD patients who received repeated intravitreal injections of bevacizumab developed 
tachyphylaxis (Forooghian et al., 2009). The median time to develop tachyphylaxis after the 
first bevacizumab injection was 100 weeks with a median of 8 injections before 
tachyphylaxis development. Other groups have also reported that tachyphylaxis with 
ranibizumab and bevacizumab for wet AMD (Schaal et al., 2008, Keane et al., 2008, Eghoj & 
Sorensen, 2011) was found. It is thought that the generation of neutralizing antibodies to 
bevacizumab did not significantly contribute to the development of tachyphylaxis 
(Forooghian et al., 2011). A combination of bevacizumab and triamcinolone acetonide (TA) 
improved the reduction of bevacizumab efficacy caused by anti-VEGF tachyphylaxis. 
Therefore, there is an urgent need to develop drugs and their drug delivery systems 
targeting other pathways not involving VEGF for patients who develop anti-VEGF 
tachyphylaxis or non-responders.  
In addition to wet AMD, dry AMD is a chronic, progressive retinal degenerative disease, 
therefore, drug delivery systems are absolutely needed. 
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Active 
ingredient 
Brand 
name 
Development 
stage 
Mode of 
action 
Administration
Route 
Excipients/ 
Carriers 
PEGylation 
Pegaptanib Macugen® Launched 
Anti-VEGF
aptamer 
IVT
injection 
PEG 
ARC1905 - 
P1 (dAMD)
P1 (wAMD)
Anti-C5
aptamer 
IVT
injection 
PEG 
E10030 - P2 (wAMD)
Anti-PDGF
aptamer 
IVT
injection 
PEG 
Sustained release 
Fluocinolone 
acetonide 
Iluvien® 
P2 (dAMD)
P2 (wAMD)
Inhibition of 
microglial 
activation 
IVT 
implant 
Polyimide/PVA
NT-501 - P2 (dAMD)
Neurotrophin
(CNTF) 
IVT
implant 
Semi-permeable 
membrane 
Brimonidine - P2 (dAMD)
α2 adrenergic 
agonist 
IVT 
implant 
PLGA 
Targeting 
Verteporfin Visudyne® Launched PDT 
IV 
injection 
Negatively-
charged 
liposome 
WST-11 Stakel® P2 (wAMD) PDT 
IV
injection 
- 
I-con1 - 
P1/2a
(wAMD) 
NK cell-mediated 
apoptosis 
IVT
injection 
- 
VEGFR 
epitope 
peptide 
- P1 (wAMD)
CTLs-mediated 
apoptosis 
SC 
injection 
- 
Gene induction 
PEDF - P1 (wAMD)
Antiangiogenesis 
by PEDF 
IVT 
injection 
Ad 
sFLT01 - P1 (wAMD) VEGF decoy 
IVT 
injection 
AAV2 
Endstatin 
Angiostatin 
RetinoStat® P1 (wAMD)
Antiangiogenesis 
by endostatin, 
angiostatin 
SRT 
injection 
EIAV 
Ad, adenovirus; AAV2, adeno-associated virus serotype 2; AMD, age-related macular degeneration;  
C5, complement factor 5; CNTF, ciliary neurotrophic factor; CTLs, cytotoxic T lymphocytes;  
EIAV, equine infectious anaemia virus; IV, intravenous; IVT, intravitreal; NK, natural killer;  
PDGF, platelet-derived growth factor; PDT, photodynamic therapy; PEDF, pigment epithelium-derived 
factor; PEG, poly(ethylene gycol); PLGA, poly(lactide-co-glycolide); PVA, poly(vinyl alcohol);  
SC, subcutaneous; SRT, subretinal; VEGF, vascular endothelial growth factor 
Table 1. Promising drug candidates for wet/dry AMD in clinical trials 
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3. Traditional formulation 
An eye-drop, irrespective of the instilled volume, often eliminates rapidly within 5 to 6 
minutes after an administration, and only a small amount (1–3%) of an eye-drop actually 
reaches the intraocular tissue. Therefore, it is difficult to provide and maintain an adequate 
concentration of drug in the precorneal area. More than 75% of applied ophthalmic solution 
is lost via nasolachrymal drainage and absorbed systemically via conjunctiva, then ocular 
drug availability is very low (Kuno & Fujii, 2011b). Generally topical applied drugs do not 
reach the posterior segment of the eye, thus, some additives or carriers to enhance the 
retention time and intraocular absorption are needed. Several eye-drops formulations are 
challenged to treat for AMD under clinical trials. 
3.1 Pazopanib 
Some studies have suggested that inhibition of VEGF signalling alone is sufficient to 
suppress choroidal neovascularization (CNV), however, others have demonstrated a more 
potent suppression of angiogenesis by inhibiting multiple tyrosine kinase receptors (Bergers 
et al., 2003, Erber et al., 2004, Kwak et al., 2000). It may be a more desirable therapeutic 
approach that drugs inhibit multiple angiogenic pathways. Pazopanib is a multi-tyrosine 
kinase inhibitor of VEGF receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth 
factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR) -1 and -3, 
cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific 
protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-
Fms). In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit 
and PDGFR-β receptors. In vivo, pazopanib inhibited VEGF-induced VEGFR-2 
phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some 
human tumor xenografts in mice (GlaxoSmithKline plc.). Pazopanib is currently prescribed 
for advanced renal cell carcinoma.  
Yafai et al. have demonstrated that eye-drop formulation of pazopanib complexed with 
cyclodextrin significantly inhibited CNV in laser-induced CNV rat model (Yafai et al., 2011). 
Since this effect was obtained by overdose of eye-drops (30 µL/eye), it is doubtful whether 
this effective inhibition of CNV resulted from a topical absorption of pazopanib. A phase II 
clinical study of pazopanib eye-drops for the treatment of wet AMD is currently underway 
(ClinicalTrials.gov. NCT01134055). Unfortunately, actual formulation of pazopanib eye-
drops used in clinical study is not disclosed. 
3.2 Tandospirone 
Serotonin (5-hydroxytryptamine; 5-HT) and its multiple receptors regulate various 
physiological functions. 5-HT1A receptor plays an important role for the control of sleep, 
feeding and anxiety. 5-HT1A receptor agonists have also neuroprotective effects in animal 
models including central nervous system ischemia (Saruhashi et al., 2002, Mauler & 
Horvath, 2005, Ramos et al., 2004, Kukley et al., 2001, Torup et al., 2000, Piera et al., 1995), 
acute subdermal hematoma (Fournier et al., 1993), traumatic brain injury (Alessandri et al., 
1999, Kline et al., 2002), excitotoxicity (Oosterink et al., 2003, Cosi et al., 2005), a Parkinson’s 
disease model animal induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (Bibbiani et 
al., 2001, Bezard et al., 2006), and sciatic nerve crush (Fournier et al., 1993). Additionally, it 
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was reported that the 5-HT1A agonists delayed the progression of motor neuron 
degeneration in pmn mice (Duong et al., 1998) and reduced lipid peroxidation in a rat 
epilepsy model (de Freitas et al., 2010). Such neuroprotective effects are considered to be 
caused by neuronal membrane hyperpolarization via G protein-coupled K+ channels, 
decreasing glutamate release, blocking Ca2+ channels or Na+ channels, activation of MAPK 
(mitogen-actiated protein kinase)/ERK (extracellular signal-regulated kinase) signalling 
pathway resulting expression of anti-apoptotic proteins and inhibition of caspase, and an 
expression of brain derived neurotrophic factor (BDNF) mRNA, S100β and nerve growth 
factor. Also 5-HT1A was expressed in rats and rabbits retina (Kusol & Brunken, 2000).  
Recently, it has been reported that tandospirone, 5-HT1A agonist, which is widely used for 
the treatment of anxiety disorders, has a neuroprotective effect for retinal lesions due to 
light-damage (Collier et al., 2009, Rhoades et al., 2009, Wang et al., 2009, Collier et al., 2010). 
The studies have also suggested tandospirone increases of MEK (mitogen-activated 
extracellular signal regulated kinase) 1/2 and ERK 1/2 phosphorylation, leading to the 
subsequent upregulation of anti-oxidant and anti-apoptotic proteins, including superoxide 
dismutase (SOD)-1, SOD-2, B-cell lymphoma (Bcl)-2 and Bcl-XL (Rhoades et al., 2009), or a 
decrease complement factors (C3, CFB, CFH) and membrane attack complex (MAC) 
deposition in the outer retina (Wang et al., 2009) (Figure 2). Currently, an eye-drops 
formulation of tandospirone (AL-8309B, Alcon Laboratories, Inc., Fort Worth, TX, U.S.) is 
under a Phase III study for the treatment of dry AMD (ClinicalTrials.gov. NCT00890097). 
Actual eye-drop formulation of tandospirone currently conducted in clinical study is not 
also disclosed. 
 
 
Fig. 2. Complement cascade 
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In the classical pathway, the cascade is initiated by the binding of C1q to antibody-antigen 
complex. The lectin pathway is initiated by the binding of carbohydrates associated with 
microbes to lectin proteins such as mannose-binding lectin (MBL). C1q and MBL form 
complexes with mannose-binding lectin-associated serine protease (MASP), which cleave C4 
into C4a and C4b,C2 into C2a and C2b. C4b binds to C2a (C4bC2a), work as a C3 convertase 
resulting degradation of C3 into C3a and C3b. C3b binds with C4bC2a to form C4bC2aC3b 
work as a C5 convertases. 
In the alternative pathway, C3 convertase is formed via a spontaneous hydrolysis of an 
internal C3 thioester into C3(H2O). C3(H2O) binds to factor B and D and forms soluble C3 
convertase; C3(H2O)Bb and subsequently formed membrane-bound C3 convertase; C3bBb   
resulting cleavage of C3 into C3a and C3b. C3b binds C3bBb to form C3bBbC3b (C5 
convertase). 
In all pathways, C5 convertases cleaves C5 to C5a and C5b. C5b initiates the formation of 
the membrane attack complex (MAC) consisting of C5b, C6, C7, C8, and C9. The MAC 
creates a pore in the cell membrane of its targets (microbes, damaged cells) leading to cell 
lysis and death. The anaphylatoxins C3a and C5a work to increase vascular permeability, 
initiate degranulation of mast cells and neutrophils, induce cytokine release from 
macrophages, and mediate leukocyte chemotaxis.  
Complement factor H (CFH) inhibits C3b through complement factor I (CFI) binding. 
Clusterin and vitronection (Vn) inhibits MAC formation by binding with a complex of C5b-
7. 
4. PEGylation 
Covalent bonding of drug molecules to poly(ethylene glycol) (PEG), referred to as 
PEGylation, is a popular approach to modify and enhance the water solubility and 
pharmacokinetic and pharmacodynamic properties of biological and small-molecule drugs. 
In general, PEGs are inert water-soluble polymers, but recently it has been reported that a 
subretinal injection of PEG induced CNV with dose-dependency via complement activation 
in mice (Lyzogubov et al., 2011). PEGs can be attached to proteins and other therapeutic 
molecules, leading to increase the hydrodynamic volume of the therapeutic molecules. In 
addition, PEGs can shield drugs from interactions with enzymes and from inactivation by 
the immune system. As a result, PEGylated drugs can exhibit prolonged half-life, higher 
stability, increased water solubility, and reduced immunogenicity. It is thought that 
conjugates bearing branched chain PEG show increased thermal stability and higher 
resistance to enzymatic degradation compared to bearing linear PEG (Hamidi et al., 2008). 
4.1 Macugen
®
 
Pegaptanib sodium is a chemically-modified oligonucleotide of 28 nucleotides which linked 
with 40 kDa branched PEG (two arms of 20 kDa linear PEG units), which binds to VEGF165. 
Pegaptanib was approved by FDA in 2004, and was both the first approved aptamer-based 
drug and the first approved pharmacotherapy for wet AMD. In rabbit eyes at 24 hours after 
an intravitreal injection, radiolabeled pegaptanib could be penetrated and distributed in the 
retina (Eyetech Inc.). In a monkey pharmacokinetics study, pegaptanib was eliminated from 
the vitreous with a half-life of 94 hours (Drolet et al., 2000), which has been increased by 3.91 
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times compared to the parent drug (non-PEGylated aptamer) (Simone Fishburn, 2008). After 
an intravitreal injection, pegaptanib is absorbed intact into the systemic circulation, but the 
concentration in plasma was 800-several thousand-fold lower than that in the vitreous. In 
addition, the elimination half-life was 9.3 hours after a single intravenous injection in rhesus 
monkeys (1 mg/kg). This “flip-flop” kinetics might cause to estimate the vitreous humor 
half-life in the vitreous from the plasma half-life in human. In clinical situation, pegaptanib 
is used as intravitreal injections of 0.3 mg once every 6 weeks. 
4.2 ARC1905 
ARC1905 (Ophthotech Corp., Princeton, NJ, U.S.) is a chemically-modified oligonucleotide 
of 39 nucleotides bound to branched PEG (two arms of 20 kDa linear PEG units), and binds 
to complement factor C5, leading to prevent the formation of key terminal fragments C5a 
and MAC (C5b-9). C5a is an important inflammatory activator inducing vascular 
permeability, recruitment and activation of phagocytes. MAC is involved to initiate cell 
lysis. Therefore, by inhibiting these C5-mediated inflammation and RPE death leading to 
geographic atrophy (GA), ARC1905 might be promising for both wet and dry AMD (Kuno 
& Fujii, 2011a). A phase I study to evaluate the safety, tolerability, and pharmacokinetic 
profile of multiple doses of intravitreal ARC1905 in combination with multiple doses of 
Lucentis® is currently in progress. In addition, it has been demonstrated by 
histopathological examination human dry AMD lesions strongly stained for C5a and MAC 
at key pathology sites (Anderson et al., 2002). A Phase I clinical trial to evaluate of an 
intravitreal ARC1905 in patients with GA is undergoing (ClinicalTrials.gov. NCT00950638). 
4.3 E10030 
E10030 (Ophthotech Corp.) is a chemically-modified oligonucleotide of 29 nucleotides 
linked with branched PEG (two arms of 20 kDa linear PEG units), and binds to PDGF-B, 
which is known to play a role of in the recruitment and maturation of pericytes that can 
increase resistance to the anti-VEGF treatment for wet AMD. PDGF and its receptor 
(PDGFR) do not act on vascular endothelial cells, but on pericytes. Therefore, inhibition of 
PDGF signalling might cause to achieve regression of neovascular vessels. Jo et al. have 
demonstrated that a combination therapy with anti-VEGF aptamer (Pegaptanib sodium) 
and anti-PDGFR-β antibody is more effective for CNV prevention and regression compared 
to monotherapy in the laser-induced CNV model (Jo et al., 2006). In an open-label Phase I 
clinical study conducted by Ophthotech, 59% of patients treated with E10030 and Lucentis® 
gained significant vision (3-line gain or better) at 12 weeks after the start of therapy. 
Interestingly, there was a mean decrease of 86% in the area of CNV at 12 weeks (Ophthotech 
Corporation). A randomized, controlled, Phase II study of E10030 in combination with 
Lucentis® for the treatment of wet AMD is currently underway (ClinicalTrials.gov. 
NCT01089517).  
5. Sustained-release systems 
To reduce the frequency of administration, many controlled drug delivery systems have 
been investigated by using biodegradable or non-biodegradable polymeric devices for the 
treatment of various retinal diseases as well as AMD (Kuno & Fujii, 2010). In general, drug 
release from biodegradable matrices consisting of poly(lactide-co-glycolide) (PLGA) is 
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degradation-controlled, in contrast, diffusion-controlled drug release is obtained from non-
biodegradable matrices such as silicone and ethylene-vinyl acetate copolymers (EVA). Some 
sustained-release formulations with constant drug release properties are currently under 
late clinical stage, but stimuli-responsive formulations with drug release triggered by 
pathophysiological condition do not exist in developmental stage yet. 
5.1 Iluvien
®
 
It has been reported that activated microglia was accumulated in the degenerative retinas 
including light-damage mouse (Zhang et al., 2005), rd mouse (Zeiss & Johnson, 2004), Royal 
College of Surgeons (RCS) rat (Thanos, 1992, Roque et al., 1996), and human eyes of RP and 
AMD (Gupta et al., 2003). Activated microglia is mainly accumulated within outer nuclear 
layer and adjacent to the RPE. In contrast, resting microglia shows a downregulated 
phenotype and a low level of membrane receptors expression; however, it quickly 
transforms into phagocyte when stimulated by infectious agents, cellular debris, and 
membrane fragments, such as lipopolysaccharides (Kreutzberg, 1996, Gehrmann, 1996, 
Pawate et al., 2004, Whitton, 2007). Within 24 hours of activation, microglial cells enlarge, 
acquire an ameboid macrophage-like shape, leading to increased microglial IgG reactivity 
and upregulation of complement receptors, and intercellular adhesion molecules (Orr et al., 
2002). Activated microglia releases cytotoxic molecules, including tumor necrosis factor 
(TNF)-α, interleukin (IL)-1β, IL-10, interferon (IFN)-γ, hydrogen peroxide, and superoxide 
anion (Orr et al., 2002, Boje & Arora, 1992, Banati et al., 1993, Kreutzberg, 1995, Kim & de 
Vellis, 2005), which may induce apoptosis in otherwise healthy cells such as photoreceptors, 
RPE, and vascular endothelial cells. Once the activating stimulus is eliminated, microglia 
quickly returns to their resting state. While the stimulus continues, however, microglial cells 
express major histocompatibility complex (MHC) class I and II (Kreutzberg, 1995, 
Nakanishi, 2003) and inflammatory glycoproteins (Aloisi, 2001), which are self-stimulating 
and stimulate/recruit other immune cells. Microglia then clusters around neurons, adheres 
to their surfaces, continually produces cytotoxins that leads to neuronal death, and 
consequently recruit and activate additional microglia (Kreutzberg, 1996, Banati et al., 1993, 
Klegeris & McGeer, 2000) via chemokines such as CCL-5 (RANTES), macrophage 
inflammation protein (MIP)-1α and MIP-1β, monocyte chemoattractant protein (MCP)-1 and 
MCP-3 (Boje & Arora, 1992, Banati et al., 1993, McGeer et al., 1993, Min et al., 2004).  
Recently, a retinal neuroprotective effect of sustained-release of a corticosteroid, 
fluocinolone acetonide (FA) for progressive retinal degeneration has been demonstrated in 
RCS rat (Glybina et al., 2009) and S334ter mutant rhodopsin transgenic rats (Glybina et al., 
2010). In both animal models, FA treatment was associated with significant decrease in the 
number of microglial cells in both the outer and inner nuclear layer. In addition, 
corticosteroids have a genomic neuroprotective effect via Trk activation, leading to a trophic 
effect (Jeanneteau et al., 2008). An injectable, rod-shaped intravitreal implant with FA 
(Iluvien®; length: 3.5 mm, diameter: 0.37 mm, formerly Medidur™) has been developed by 
Alimera Sciences (Alpharetta, GA, U.S.) for the treatment of dry AMD under Phase II study 
(ClinicalTrials.gov. NCT00695318). Furthermore, the feasibility study of Medidur™ as a 
maintenance therapy for wet AMD patients who have been treated with Lucentis® for at 
least 6 months and have reached a plateau is currently in a pilot Phase II (ClinicalTrials.gov. 
NCT00605423). 
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5.2 Ranibizumab-loaded microspheres 
Despite the remarkable effectiveness for treating wet AMD and other retinal diseases by 
Lucentis®, patients and physicians have been hoping for an alternative to the frequent 
intravitreal injections. SurModics, Inc. (Eden Prairie, MN, U.S.) and Genentech, Inc. have 
been developing a biodegradable microparticles incorporated ranibizumab currently under 
preclinical stage (SurModics Inc). It is hoped that ranibizumab-loaded microparticles can 
deliver ranibizumab over a period of approximately 4 to 6 months (Helzner, 2010). 
5.3 NT-501 
Neuroprotective effect of ciliary neurotrophic factor (CNTF) has been confirmed in various 
animal models of retinal degeneration including light-damaged rats, mutant rhodopsin 
transgenic mice, and a dog model. In addition, the long-term effect of CNTF has been shown 
by repeated intravitreal injections of CNTF in an autosomal dominant feline model of rod-
cone dystrophy or an intravitreal injection of adeno-associated viral (AAV) vectors 
incorporated CNTF-cDNA in mutant rhodopsin transgenic rats. Neurotech Pharmaceuticals, 
Inc. (Lincoln, RI, U.S.) has been developing “Encapsulated Cell Technology”, which 
provides an extracellular delivery of CNTF through long-term and stable intraocular release 
at constant doses through a device implanted in the vitreous. It contains human RPE cell 
line (ARPE-19) genetically modified to secrete recombinant human CNTF. The device (NT-
501) consists of a sealed semi-permeable membrane capsule surrounding a scaffold of 6 
strands of polyethylene terephthalate yarn, which can be loaded with cells (length; 6 mm, 
diameter; 1 mm). The device is surgically implanted in the vitreous through a tiny scleral 
incision and is anchored by a single suture through a titanium loop at one end of the device. 
The semi-permeable membrane allows the outward diffusion of CNTF and other cellular 
metabolites and the inward diffusion of nutrients necessary to support the cell survival in 
the vitreous cavity while protecting the contents from host cellular immunologic attack.  
A Phase I clinical trial for RP has been completed and demonstrated well tolerated for 6 
months implantation (Sieving et al., 2006). Eighteen-month results in a Phase II study for 
patients with GA with dry AMD were reported (Jaffe et al., 2010) (Zhang et al., 2011); 
participants were randomized in a 2:1:1 ratio to receive a high (20 ng/day) or low dose (5 
ng/day) NT-501, or to sham surgery, respectively. Among eyes with baseline best corrected 
visual acuity (BCVA) 20/63, the mean BCVA in the high dose group was 10.5 and 10.0 
letters greater than the low dose/sham group at 12 months (p=0.03) and 18 months, 
respectively. Stabilized visual acuity was accompanied by the corresponding structural 
changes; NT-501 treatment resulted in a dose-dependent increase of retinal thickness as 
early as 4 months after implantation and this increase was maintained through 6, 12 and 18 
months (p<0.001). The growth rate of GA area was reduced in treated eyes compared to 
fellow eyes at 12 and 18 months. In addition, NT-501 also prevented secondary cone 
degeneration in RP patients (Talcott et al., 2011). 
5.4 Brimonidine-loaded intravitreal implant 
Brimonidine is an α2 adrenergic agonist, which can release various neurotrophins including 
BDNF, CNTF (Lonngren et al., 2006, Kim et al., 2007), and b-FGF (Lai et al., 2002). These 
neurotrophins have potential to prevent apoptosis of photoreceptors and/or RPE (Azadi et 
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al., 2007, Zhang et al., 2009). A biodegradable, rod-shaped PLGA intravitreal implant 
containing brimonidine tartrate is now in a Phase II clinical study for dry AMD 
(ClinicalTrials.gov. NCT00658619) by Allergan Inc. (Irvine, CA, U.S.). 
6. Targeting systems 
Selective targeting to the neovascular lesions is desired for the improvement of therapeutic 
efficacy and the reduction of normal tissue damage. Active targeting to neovascular 
endothelial cells using highly-expressed specific molecules on endothelial cells has been 
widely investigated for the treatment of CNV. In addition, immunotherapy in conjunction 
with active targeting is also developing for regression of CNV. 
6.1 Visudyne
®
 
Visudyne® (QLT Ophthalmics, Inc., Menlo Park, CA, U.S.) is an intravenous liposomal 
formulation containing a photosensitizer, verteporfin in PDT for predominantly classic 
subfoveal CNV due to wet AMD, pathologic myopia or presumed ocular histoplasmosis 
(QLT Ophthalmics). Plasma lipoproteins, such as low-density lipoprotein (LDL), have been 
proposed to enhance the delivery of hydrophobic verteporfin to malignant tissue since 
tumor cells have increased the number of LDL receptors (Allison et al., 1994). In addition, 
liposomes composed of negatively charged phospholipids such as phosphatidylglycerol are 
taken up into tumor cells by LDL receptor-mediated endocytosis (Amin et al., 2002). It is 
thought that verteporfin released into the blood stream from liposomes is associated with 
LDL and is taken up into neovascular tissue, on the other hand, un-dissociated verteporfin, 
which is still encapsulated in the liposomes, is selectively accumulated in neovascular 
endothelial cells via LDL receptor-mediated endocytosis, since phosphatidylglycerol is the 
major constituent of Visudyne®.  
Since LDL receptors are also expressed in RPE as well as endothelial cells (Hayes et al., 
1989), verteporfin PDT causes damage to RPE associated with photoreceptor lesions. 
Indeed, adverse effects by verteporfin PDT have been reported (Tzekov et al., 2006, Ozdemir 
et al., 2006, Oner et al., 2005a, 2005b) in clinical situation. To enhance PDT effects and 
minimize damage of normal tissues, highly selective targeting might be necessary. 
6.2 WST-11 (Stakel
®
) 
Serum albumin has the unique ability to reversibly or covalently bind various endogenous 
or exogenous ligands with high affinity, resulting in working as a transporter and depot 
protein for various compounds (Kragh-Hansen, 1990). The cellular uptake of serum albumin 
via receptor (albondin)-mediated endocytosis (Schnitzer & Oh, 1994, John et al., 2001) might 
cause highly efficient intracellular trafficking. WST-11 (Stakel®, Steba Biotech S.A., Toussus-
Le-Noble, France) is a negatively charged, water-soluble bacteriochlorophyll derivative with 
maximum absorption wavelength in the near infrared (753 nm) and rapid clearance from the 
body (Mazor et al., 2005, Brandis et al., 2005). WST-11 binds to serum albumin and has 
potent anti-neovascularization via the generation of hydroxyl radicals when stimulated by 
the proper light wavelength. Berdugo et al. have demonstrated that WST-11 PDT, which 
selectively occludes CNV, could be achieved in laser-induced CNV model of rats without 
the damages to the retinal tissues such as RPE and photoreceptors unlike verteporfin PDT. 
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Steba Biotech S.A. currently conducts a Phase II study for WST-11 PDT in wet AMD patients 
(ClinicalTrials.gov. NCT01021956). 
6.3 I-con1 
Tissue factor (TF) acts as a primary cellular initiator of blood coagulation, and has following 
additional biological functions involving neovascularization. TF can induce angiogenesis by 
upregulating VEGF and also promote angiogenesis via TF-initiated coagulation pathways. 
Thrombin stimulation of platelets, which is a major VEGF transporter, releases VEGF 
(Mohle et al., 1997), leading to stimulate endothelial cells to induce and expose more TF, 
following further thrombin formation. In addition, TF expressed in surgically excited CNV 
membrane and AMD eyes was related to active inflammation site accompanied by an 
accumulation of macrophages and fibrin deposition (Grossniklaus et al., 2002). It has been 
reported that TF mRNA expression in AMD was 32-fold higher than in the non-AMD (Cho 
et al., 2011) and TF was expressed only on neovascular endothelial cells not normal vascular 
endothelial cells (Contrino et al., 1996). Therefore, TF might be a specific target for 
neovascular tissues.  
hI-con1 (Iconic Therapeutics, Inc., Atlanta, GA, U.S.) is a chimeric IgG-like homodimeric 
protein composed of a targeting-domain (mutated, inactivated factor VIIa, which is a ligand 
for TF) fused to an effector-domain (human IgG Fc) with an intact hinge region (Iconic 
Therapeutics). Once hI-con1 binds to TF on the surface of neovascular endothelial cells, the 
effector-domain mobilizes natural killer (NK) cells mediated via the Fc receptor, leading to 
activating the complement cascade (Wang et al., 1999, Hu & Li, 2010) and inducing the 
selective apoptosis of TF-expressing cells. Consequently, NK cells do not induce apoptosis 
of other cells including normal vascular tissue and RPE and neural retina. Bora et al. have 
demonstrated that intravitreal mouse factor VII-human IgG1 Fc chimeric conjugate inhibited 
CNV in a laser-induced CNV model in mice (Bora et al., 2003). In addition, Tezel et al. 
reported that this immunoprotein could selectively regress already-established CNV in 
laser-induced pig model (Tezel et al., 2007). A Phase I/IIa study of intravitreal hI-con1 for 
wet AMD is currently underway (Iconic Therapeutics). 
6.4 Anti-VEGFR vaccine 
VEGFR2 (Flk-1) plays a pivotal role in endothelial cell proliferation and migration (Millauer 
et al., 1993, Risau, 1997), and is upregulated during CNV formation (Wada et al., 1999). 
VEGFR2 vaccination therapy has been progressed in the cancer field (Niethammer et al., 
2002, Wada et al., 2005, Pan et al., 2008). The strategy of VEGFR vaccination therapy for wet 
AMD is to induce apoptosis of neovascular endothelial cells, and inhibition and regression 
of CNV by cytotoxic T lymphocytes (CTLs). Takahashi et al. have demonstrated that 
vaccination with human VEGFR2-derived epitope peptide (VEGFR2-773) significantly 
inhibited CNV in laser-induced A2/Kb transgenic mice, which express chimeric human-
mouse MHC class I molecule, and this chimeric molecule shows 71% concordance with the 
human CTL repertoire (Vitiello et al., 1991). VEGFR2 peptide induces CTLs in the 
histocompatibility leukocyte antigen (HLA) class I-restricted manner (Wada et al., 2005).  
It is thought that the advantage of VEGFR2 vaccination is long-lasting therapeutic effect on 
the vascular endothelial cells since endothelial cells are genetically stable and do not show 
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the downregulation of HLA class I molecules (Niethammer et al., 2002). It has been reported 
that, 60.8% and 19.9% in Japanese population share a common HLA-A*2402 allele and HLA-
A*0201 allele, respectively (Date et al., 1996). HLA-A*2402 restricted VEGFR1- and VEGFR2-
derived peptide vaccination therapy for wet AMD is conducted under a Phase I study in 
Japan (ClinicalTrials.gov. NCT00791570). 
7. Gene therapy 
Adenoviral (Ad) and AAV vectors are non-integrating and transduce both dividing and 
non-dividing cells. However, Ad and AAV elicit CTLs-mediated immune responses 
resulting in limitation of duration of transgene expression (McConnell & Imperiale, 2004). 
Helper-dependent Ad can extend the duration of ocular expression from less than 3 months 
to up to 1 year (Lamartina et al., 2007). Lentiviral vectors can induce stable, long-term 
transgene expression in the retinal (Balaggan et al., 2006). Lentivirus, which are integrating 
vectors, have the risk of insertional oncogenesis. Highly deleted (Molina et al., 2004), self-
inactivating (Berkowitz et al., 2001) and non-integrating (Yanez-Munoz et al., 2006) lentiviral 
vectors have been developed as safer vectors. In general, subretinal injections are conducted 
in the operating room and are more invasive than intravitreal injections. If a single 
subretinal injection of a vector to provide prolonged suppression of CNV, it might be 
reasonable and feasible to substitute for repeated intravitreal injections of Lucentis®. 
7.1 Pigment epithelium-derived factor 
AdPEDF.11D is E1-, partial E3-, and E4-deleted Ad vector, which is replication-deficient, 
expressing pigment epithelium-derived factor (PEDF). A Phase I study of intravitreal 
AdPEDF.11D conducted by GenVec, Inc. (Gaithersburg, MD, U.S.) has completed. The 
results have shown that several complications such as mild inflammation, corneal edema, 
and elevated IOP were observed in some patients, but systemic hematogenous vector 
spread and systemic immune responses were not observed. Although hyperpermeability 
appeared to resolve in some patients received high-dose AdPEDF.11D, unfortunately, 
patients received high-dose (108-109.5 particle units) had no change in visual acuity 
compared to low-dose (106-107.5 particle units) patients whose visual acuity appeared to 
worsen over the course of study (Campochiaro et al., 2006). Further clinical trials have not 
progressed after the completion of a Phase I study in 2006. 
7.2 sFLT01 
sFLT01 is an antiangiogenic fusion protein consisting of the VEGF/placental growth factor 
(PIGF) binding domain of human Flt-1 (hVEGFR1) fused to the Fc portion of human IgG1 
through a polyglycine linker (Bagley et al., 2011). Therefore, sFLT01 acts as a VEGF decoy. It 
has been reported that an intravitreal injection of AAV serotype 2 (AAV2) vector coding for 
sFLT01 (AAV2-sFLT01) significantly inhibited CNV in laser-induced CNV model of mice 
and monkeys (Lukason et al., 2011) and retinal neovascularization in mouse oxygen-
induced retinopathy model (Pechan et al., 2009). Interestingly, sFLT01 expression in the 
retina continued for up to 12 months after an intravitreal injection (Pechan et al., 2009). A 
Phase I clinical trial of AAV2-sFLT01 is currently conducted by Genzyme (Cambridge, MA, 
U.S.) (ClinicalTrials.gov. NCT01024998). 
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7.3 RetinoStat
®
 
RetinoStat® (Oxford Biomedica, Oxford, UK) is an equine infectious anaemia virus (EIAV)-
based lentiviral vector expressing human endostatin and angiostatin, which are endogenous 
angiostatic factors. EIAV can transduce both dividing and non-dividing cells. Endostatin is 
an internal fragment of collagen XVIII, and downregulates the expression of the 
antiapoptotic proteins such as Bcl-2 and Bcl-XL (Dhanabal et al., 1999), and may interact with 
endothelial cell surface receptors and integrins leading to apoptosis of endothelial cells in 
active neovascularization, but not mature vasculature. In addition, endostatin blocks VEGF 
signalling via a direct interaction with VEGFR2 (Kim et al., 2002). Angiostatin is a cleavage 
product of plasminogen, which has the kringle domains, and promotes apoptosis of 
proliferating vascular endothelial cells similar to endostatin (Claesson-Welsh et al., 1998, 
Hari et al., 2000). Also, angiostatin downregulates VEGF expression (Hajitou et al., 2002, 
Sima et al., 2004). RetinoStat® incorporates RPE-specific vitelliform macular dystrophy gene 
(VMD2) promoter, leading to limited transgene expression to RPE after a subretinal 
injection (Kan et al., 2009). Kachi et al. have demonstrated that a subretinal injection of 
RetinoStat® significantly inhibited CNV in laser-induced CNV model of mice (Kachi et al., 
2009). A Phase I study of subretinal RetinoStat® in wet AMD patients is currently ongoing 
(ClinicalTrials.gov. NCT01301443).  
8. Devices 
Mechanical devices have been developing for the purpose of more selective drug targeting, 
chronic infusion, or stimuli-responsive drug release.  
8.1 Microcatheter 
A microcatheter, iTrack™ 250A (iScience Interventional™, Menlo Park, CA, U.S.) is 
originally designed for canaloplasty (iScience Interventional™), which is a new treatment 
for glaucoma (Lewis et al., 2009, 2011). The iTrack™ 250A consists of an optical fiber to 
allow transmission of light to the microcannula tip for surgical illumination and guidance. 
Recently, this microcatheter is challenged to use for suprachoroidal drug delivery (Olsen, 
2007, Rizzo et al., 2010). The pharmacokinetic study of suprachoroidal delivery of TA in pigs 
has shown that TA remained in the ocular tissues for at least 120 days, and the systemic 
exposure was very low (Olsen et al., 2006). In contrast, the study to compare the 
pharmacokinetics of bevacizumab between intravitreal and suprachoroidal injections to pigs 
(Olsen et al., 2011) reported that the profile of intravitreal injections of bevacizumab was 
more sustained than that of suprachoroidal injections at the same dosage level. Intravitreal 
injected bevacizumab distributed more to the inner retina, whereas suprachoroidal injected 
bevacizumab distributed primarily to the choroid, RPE, and photoreceptor outer segments. 
Scharioth et al. have tried to conduct suprachoroidal injections of bevacizumab in the wet 
AMD patients who were non-responder of intravitreal anti-VEGF therapy and/or initial 
BCVA < 0.05 (Scharioth et al., 2011). In the case of the patient who had a history of 21 
intravitreal anti-VEGF injections with poor response to this therapy, and BCVA was 0.1, a 
significant reduction of pigment epithelial detachment was observed at 4 weeks after a 
suprachoroidal injection of bevacizumab, BCVA slightly improved to 0.16 and the subfoveal 
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membrane totally disappeared at 8 weeks. During 6 months of follow-up, no signs of 
recurrence were observed. 
8.2 Micropump™ system 
A microelectromechanical systems (MEMS) drug delivery device is investigated for the 
treatment of chronic and refractory ocular diseases (Lo et al., 2009, Saati et al., 2010). MEMS 
device can be re-filled with the drug solution, giving long-term drug therapy which avoids 
repeated surgeries. The first generation of MEMS is a manually-controlled system limited by 
variations in the drug-release duration and force applied for depressing of the reservoir. To 
resolve this problem, the next generation device consists of an electrolysis chamber with 
electrolysis actuation to precisely delivery the desired dosage volume, a drug reservoir with 
refill port, battery and electronics. Biocompatible and flexible parylene is used to construct 
the MEMS. Battery and wireless inductive power transfer can be used to drive electrolysis. 
Electrolysis is a low power process in which the electrochemically-induced phase change of 
water to hydrogen and oxygen gas generates pressure in the reservoir forcing the drug 
through the cannula (Saati et al., 2010). The reservoir is implanted in the subconjunctival 
space and flexible cannula is inserted through incision into the anterior or posterior 
segment. Gonzalez-Soto et al. have demonstrated that a slower prolonged infusion of the 
same volume and concentration of intravitreal ranibizumab is equivalent to a bolus 
intravitreal injection of ranibizumab to human VEGF-induced retinal hyperpermeability 
model of rabbits (Gonzalez-Soto et al., 2011).  
Replenish, Inc. (Pasadena, CA, U.S.) plans to enter clinical trials for a refillable and 
programmable pump that would be implanted in the eye to feed medicine for glaucoma or 
AMD. The Replenish device can last more than 5 years before needing replacement, much 
longer than current treatments (Flanigan, 2009). 
8.3 ODTx 
On Demand Therapeutics, Inc. (Menlo Park, CA, U.S.) has been developing a multi-reservoir 
implantable device for laser-activated drug delivery to the posterior segment of the eye 
(RetinaToday, 2010) (On Demand Therapeutics Inc). The injectable, biocompatible, non-
resorbable device (ODTx) contains reservoirs designed for drug release in optimized doses. 
The reservoirs are capable of storing small- or large-molecule drugs that can be released via 
a standard, non-invasive laser activation procedure. The multiple reservoir system allows 
for ophthalmologists to control drug delivery by activating specific reservoirs, while 
unactivated reservoirs remain intact. Unfortunately, clinical trials of ODTx have not 
progressed yet. 
9. Conclusion 
Recent advances in drug delivery systems under clinical situation and in the late 
experimental stages are described in this chapter. AMD is chronic, progressive and 
refractory retinal degenerative disease, and induced by complex pathophysiological 
conditions. It is necessary to consider further the most efficacious combinations of optimal 
drugs, doses, routes, and drug release patterns (sustained-release, pulsatile-release, or 
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controlled-release by responding to a trigger) based on the pathophysiology and 
progressive courses of the targeted disease. 
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